Becton, Dickinson(BDX) - 2026 Q1 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenue for Q1 2026 was $5.3 billion, reflecting a 0.4% increase year-on-year, with new BD growing by 2.5% [5][18] - Adjusted gross margin was 53.4%, down 140 basis points from the previous year, primarily due to tariffs [20] - Adjusted EPS was $2.91, a decrease of 15.2% year-on-year, driven mainly by tariff impacts [21] - Free cash flow for the quarter was $548 million, with a conversion rate of 66%, up from 59% in the prior year [22] Business Line Data and Key Metrics Changes - Medical Essentials experienced mixed performance, with expected order timing dynamics affecting MDS, but continued share gains in the US vascular access management portfolio [18] - Connected Care delivered mid-single-digit growth, led by APM, which grew high single digits [18] - Biopharma Systems grew low single digits, with double-digit growth in biologics, particularly GLP-1s, offset by lower vaccine demand [19] - Interventional and surgery segments both delivered solid mid-single-digit growth, with advanced tissue regeneration and infection prevention portfolios performing well [19] Market Data and Key Metrics Changes - Growth in China was impacted by volume-based procurement (VBP) and market dynamics, but overall volume growth was positive despite price compression [42] - The US market showed strong performance in several categories, including pharmacy automation, which grew double digits [61] Company Strategy and Development Direction - The company is focused on a balanced capital allocation strategy, prioritizing share repurchases, dividends, and targeted tuck-in M&A in high-growth markets [8][80] - The strategic priorities include competing, innovating, and delivering, with significant investments in commercial capabilities and R&D to drive growth [11][73] - The company aims to leverage trends in healthcare, such as the rise of smart devices and the shift towards lower-cost care settings, to position itself for future growth [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trajectory of the business, maintaining a prudent approach to guidance for fiscal 2026, with expectations of low single-digit revenue growth [24][25] - The company anticipates that pricing dynamics will improve as VBP in China abates, potentially leading to positive pricing in the future [91] Other Important Information - The completion of the life sciences transaction with Waters is seen as a significant milestone, providing a $4 billion cash distribution, with plans for $2 billion in share repurchases and $2 billion for debt paydown [8][24] - The company has reduced its manufacturing network by nearly half, which is expected to lower costs and improve operational efficiency [16][56] Q&A Session Summary Question: Guidance for Q2 revenue and EPS - Management indicated that Q2 guidance reflects modest timing benefits and that core growth drivers remain intact, with no significant changes expected [27][28] Question: Structural changes affecting mid-single-digit growth - Management confirmed that the fundamentals across the majority of the portfolio remain strong, with ongoing investments in high-growth areas [33][34] Question: Impact of Alaris and vaccines in China - Management expects Alaris to improve in 2027, with vaccines anticipated to be a smaller portion of revenue moving forward [40][42] Question: Pricing environment and innovation impact - Management noted a stable pricing environment with slight positive pricing outside of China, and expects new product innovations to help drive pricing and organic revenue growth [91]